|
Real-time
Euronext Paris
05:12:41 2026-10-13 am EDT
|
5-day change | 1st Jan Change | ||
| 72.47 EUR | +1.22% |
|
+2.63% | -12.39% |
| Oct. 07 | Pharmaceutical Group Sues US Government Over Medicare Drug Pricing Rule | MT |
| Oct. 07 | European Equities Traded in US as ADRs Fall in Wednesday Trading | MT |
| Market Cap | 85.78B 95.82B 79.97B 72.53B 137B 9,160B 138B 961B 376B 4,727B 360B 352B 15,211B | P/E 2026 * |
11.6x | P/E 2027 * | 10x |
|---|---|---|---|---|---|
| Enterprise Value | 97.12B 108B 90.53B 82.12B 155B 10,371B 156B 1,088B 426B 5,352B 408B 398B 17,221B | EV / Sales 2026 * |
2.05x | EV / Sales 2027 * | 1.86x |
| Free-Float |
88.34% | Yield 2026 * |
5.94% | Yield 2027 * | 6.29% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| SAN | Real-time | |
CBOE
| SAN | Real-time | |
|
Borsa Italiana
| 1SAN | End-of-day quote | |
|
Xetra
| SNW | Delayed | |
|
Tradegate
| SNW | Real-time | |
|
OTC Markets
| SNYNF | Delayed | |
|
Boerse Muenchen
| SNW | Real-time | |
|
Bulgaria S.E.
| SNW | End-of-day quote | |
|
CBOE
| 0O59 | Real-time | |
|
Swiss Exchange
| SAN | Delayed | |
|
Wiener Boerse
| SANO | End-of-day quote | |
|
Deutsche Boerse AG
| SNW | Delayed | |
|
London S.E.
| 0O59 | Delayed | |
|
Börse Stuttgart
| SNW | Delayed |
Last Transcript: Sanofi
| 1 day | +1.26% | ||
| 1 week | +2.68% | ||
| Current month | -0.19% | ||
| 1 month | -3.88% | ||
| 3 months | -5.97% | ||
| 6 months | -8.70% | ||
| Current year | -12.35% |
| 1 week | 70.51 |  | 72.65 |
| 1 month | 69.75 | | 75.96 |
| Current year | 69.75 | | 84.97 |
| 1 year | 69.75 | | 91.15 |
| 3 years | 69.75 | | 110.88 |
| 5 years | 69.75 | | 110.88 |
| 10 years | 62.88 | | 110.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 2026-04-30 | |
| Director of Finance/CFO | 64 | 2024-03-31 | |
Paulo Fontoura
CTO | Chief Tech/Sci/R&D Officer | - | 2026-08-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 61 | 2019-04-29 | |
Rachel Duan
BRD | Director/Board Member | 56 | 2020-04-27 |
Lise Kingo
BRD | Director/Board Member | 65 | 2020-04-27 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/20/26 | Buy | Chief Executive Officer | 1,506 | 0.0001% | ||
| 8/20/26 | Buy | Head of Human Resources | 54 | 0.0000% | ||
| 8/20/26 | Buy | Executive/Senior Manager | 840 | 0.0001% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.23% | +2.68% | -13.85% | -29.87% | 95.82B | |
| +0.28% | +3.46% | +41.89% | +93.71% | 1,054B | |
| +0.88% | +4.27% | +38.28% | +68.70% | 636B | |
| +1.68% | +5.78% | +21.96% | +89.56% | 497B | |
| -0.10% | +4.24% | +69.15% | +40.41% | 359B | |
| +1.65% | +4.83% | +26.40% | +43.78% | 345B | |
| +1.50% | +4.03% | +16.65% | +39.28% | 273B | |
| +2.00% | +2.84% | -3.35% | +12.06% | 246B | |
| +0.65% | +3.62% | +43.93% | +46.50% | 226B | |
| -0.49% | +4.01% | +28.38% | +95.97% | 187B | |
| Average | +0.88% | +3.06% | +26.94% | +50.01% | 391.8B | |
| Weighted average by Cap. | +0.70% | +3.17% | +33.42% | +65.28% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 47.35B 52.89B 44.14B 40.03B 75.51B 5,056B 75.98B 530B 208B 2,609B 199B 194B 8,396B | 50.47B 56.37B 47.04B 42.67B 80.48B 5,389B 80.99B 565B 221B 2,781B 212B 207B 8,949B |
| Net income | 7.3B 8.15B 6.8B 6.17B 11.64B 779B 11.71B 81.75B 32B 402B 30.62B 29.94B 1,294B | 8.81B 9.85B 8.22B 7.45B 14.06B 941B 14.14B 98.74B 38.65B 486B 36.98B 36.16B 1,563B |
| Net Debt | 11.34B 12.66B 10.57B 9.58B 18.08B 1,210B 18.19B 127B 49.71B 625B 47.57B 46.51B 2,010B | 8B 8.94B 7.46B 6.77B 12.76B 855B 12.84B 89.66B 35.1B 441B 33.58B 32.84B 1,419B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-13 | €72.47 | +1.22% | 207,390 |
| 26-10-12 | €71.60 | +0.11% | 1,843,195 |
| 26-10-09 | €71.52 | +0.83% | 1,832,721 |
| 26-10-08 | €70.93 | -1.23% | 2,089,278 |
| 26-10-07 | €71.81 | +1.70% | 1,549,500 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SAN Stock
Select your edition
All financial news and data tailored to specific country editions
